drugset / Trial / NCT01481116

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

NCT01481116

Phase 3 Terminated 2454 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM). The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM).

Timeline

Start
2012-01
Primary completion
2014-03
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasiglifam Small molecule 25 mg Oral
Subject Fasiglifam Small molecule 50 mg Oral
Comparator Glimepiride Small molecule 2 mg Oral